ProCE Banner Activity

ATTRACTION-5: Phase III Study of Adjuvant Nivolumab + Chemotherapy After Gastrectomy for Pathologic Stage III Gastric or Gastroesophageal Junction Cancer

Conference Coverage
Slideset

Addition of nivolumab to adjuvant chemotherapy after gastrectomy for pathologic stage III gastric or gastroesophageal junction cancer did not result in improved RFS.

Released: June 04, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Merck Sharp & Dohme Corp., Novocure, and Seagen.

Merck Sharp & Dohme Corp.

Novocure

Seagen